Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.75.
NKTX has been the subject of a number of analyst reports. Wall Street Zen cut Nkarta from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. TD Cowen initiated coverage on Nkarta in a report on Tuesday, June 23rd. They set a “buy” rating on the stock. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Nkarta in a research note on Wednesday, May 13th. Evercore set a $9.00 target price on Nkarta in a report on Monday, May 18th. Finally, Mizuho decreased their target price on Nkarta from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st.
Check Out Our Latest Stock Report on NKTX
Nkarta Price Performance
Nkarta (NASDAQ:NKTX – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02. As a group, research analysts predict that Nkarta will post -1.43 earnings per share for the current fiscal year.
Institutional Trading of Nkarta
Several large investors have recently modified their holdings of NKTX. Abel Hall LLC bought a new position in Nkarta in the 4th quarter worth $27,000. The Manufacturers Life Insurance Company bought a new position in shares of Nkarta in the first quarter worth about $30,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Nkarta during the 4th quarter worth about $37,000. Forefront Analytics LLC lifted its position in shares of Nkarta by 41.0% during the 3rd quarter. Forefront Analytics LLC now owns 39,452 shares of the company’s stock worth $82,000 after purchasing an additional 11,473 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Nkarta by 74.9% during the 1st quarter. Sei Investments Co. now owns 40,046 shares of the company’s stock valued at $84,000 after purchasing an additional 17,148 shares during the period. 80.54% of the stock is owned by institutional investors.
About Nkarta
Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.
Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.
Featured Articles
- Five stocks we like better than Nkarta
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
